Trade

with

Puma Biotechnology Inc
(NYSE: PBYI)
AdChoices
228.08
+2.55
+1.13%
After Hours :
230.00
+1.92
+0.84%

Open

225.70

Previous Close

225.53

Volume (Avg)

147.63k (546.18k)

Day's Range

223.51-230.69

52Wk Range

33.70-279.37

Market Cap.

6.79B

Dividend Rate ( Yield )

-

Beta

-2.35

Shares Outstanding

30.12M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 0

    • Net Income

    • -54.66M

    • Market Cap.

    • 6.79B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • -2.35

    • Forward P/E

    • -

    • Price/Sales

    • -

    • Price/Book Value

    • 41.15

    • Price/Cash flow

    • -105.26

      • EBITDA

      • -54.41M

      • Return on Capital %

      • -54.85

      • Return on Equity %

      • -64.85

      • Return on Assets %

      • -54.85

      • Book Value/Share

      • 5.55

      • Shares Outstanding

      • 30.12M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/20/2014
      Buy
        • 1 Year Price Target

        • 325.00

        • Credit Rating

        • -

        • Analysts

        • 1

        • EPS Estimate

        • -4.58

        • Cashflow Estimate

        • -4.56

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 6.57

              • 2.92

              • Quick Ratio

              • 6.45

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.17

              • 2.21

              • Book Value/Share

              • 5.55

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -70.92

                • 196.08

                • P/E Ratio 5-Year High

                • -92.05

                • 634.30

                • P/E Ratio 5-Year Low

                • -3.62

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.12

                • Price/Book Value

                • 38.76

                • 8.26

                • Price/Cash Flow Ratio

                • -105.26

                • 47.39

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -64.85

                    (-)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -54.85

                    (-524.40)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -64.85

                    (-)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -54.83M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -105.26
                  Ownership

                  Institutional Ownership

                  -

                  Top 10 Institutions

                  70.96%

                  Mutual Fund Ownership

                  49.93%

                  Float

                  67.18%

                  5% / Insider Ownership

                  0.52%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    1,204,627

                  • 2.96

                  • 4.00

                  • T. Rowe Price Health Sciences Fund

                  •  

                    1,020,205

                  • 12.85

                  • 3.39

                  • T. Rowe Price New Horizons Fund

                  •  

                    832,011

                  • 17.81

                  • 2.76

                  • Lord Abbett Fundamental Equity

                  •  

                    612,700

                  • 0.00

                  • 2.03

                  • Bb Biotech AG

                  •  

                    576,991

                  • 389.01

                  • 1.92

                  • Franklin Biotechnology Discovery

                  •  

                    462,600

                  • 46.58

                  • 1.54

                  • T. Rowe Price Mid Cap Growth Fund

                  •  

                    450,000

                  • 0.00

                  • 1.49

                  • Vanguard Small Cap Index

                  •  

                    444,659

                  • -0.36

                  • 1.48

                  • Vanguard Total Stock Mkt Idx

                  •  

                    418,089

                  • 0.80

                  • 1.39

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Adage Capital Partners Gp LLC

                  •  

                    5,686,668

                  • 0.00%

                  • 18.88

                  • T. Rowe Price Associates, Inc.

                  •  

                    3,210,367

                  • +8.63%

                  • 10.66

                  • Fidelity Management and Research Company

                  •  

                    1,518,618

                  • -33.77%

                  • 5.04

                  • Vanguard Group, Inc.

                  •  

                    1,492,173

                  • +0.10%

                  • 4.95

                  • Lord, Abbett & Co LLC

                  •  

                    1,355,006

                  • -1.53%

                  • 4.49

                  • Franklin Advisers, Inc.

                  •  

                    763,034

                  • -4.31%

                  • 2.53

                  • State Street Corp

                  •  

                    651,349

                  • +22.60%

                  • 2.16

                  • BlackRock Fund Advisors

                  •  

                    596,848

                  • +5.12%

                  • 1.98

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Distressed

                  Style

                  Small Growth

                  Puma Biotechnology Inc, a Delaware corporation was incorporated on April 27, 2007. The Company is a development-stage biopharmaceutical company that acquires and develops innovative products for the treatment of various forms of canc...moreer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The Company currently licenses the rights to three drug candidates: PB272 (neratinib (oral)), which are being developed for the treatment of advanced breast cancer patients, non-small cell lung cancer and patients with HER2 mutation-positive solid tumors; PB272 (neratinib (intravenous)), which are being developed for the treatment of advanced cancer pati...moreents; and PB357, which it believes can serve as a backup compound to PB272, and which are being evaluated for further development. The Company focused on developing neratinib for the treatment of patients with human epidermal growth factor receptor type 2, or HER2-positive, breast cancer, HER2 mutated non-small cell lung cancer, HER2-negative breast cancer that has a HER2 mutation and other solid tumors that have an activating mutation in HER2. Therapeutic strategies, such as the use of Herceptin (trastuzumab), Perjeta (pertuzumab), and Kadcyla (T-DM1), produced by Genentech, and Tykerb (lapatinib), produced by GlaxoSmithKline, given either alone or in combination with chemotherapy, have been developed to improve the treatment of this cancer by binding to the HER2 protein. The Company licenses the exclusive worldwide rights to its current drug candidates from Pfizer Inc., or Pfizer, which had previously been responsible for the clinical trials regarding neratinib. The Company has modified Pfizer’s clinical development strategy and during the next 12 to 18 months plan to: commence Phase III clinical trials evaluating the use of with HER2-positive metastatic breast cancer who have previously failed two or more prior treatment; continue the ongoing Phase II clinical trial of neratinib in the neoadjuvant treatment of HER2 positive breast cancer, in patients with HER2 positive metastatic breast cancer that has metastasized to the brain; and continue to evaluate the application of neratinib in the treatment of other forms of HER2 positive cancers where there may be unmet medical needs. The Company’s competitors include Genentech, GlaxoSmithKline, Roche, Boehringer Ingelheim, Takeda, Array Biopharma and Ambit Biosciences.lessless

                  Key People

                  Alan H. Auerbach

                  CEO/Chairman of the Board/Director/President/Secretary

                  Charles R. Eyler

                  CFO/Chief Accounting Officer/Senior VP, Divisional/Treasurer

                  Mr. Erin Jones

                  Vice President, Divisional

                  Mr. Thomas R. Malley

                  Director

                  Jay M. Moyes

                  Director

                  • Puma Biotechnology Inc

                  • 10880 Wilshire Boulevard

                  • Los Angeles, CA 90024

                  • USA.Map

                  • Phone: +1 424 248-6500

                  • Fax: +1 424 248-6501

                  • pumabiotechnology.com

                  Incorporated

                  2007

                  Employees

                  72

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: